Your browser doesn't support javascript.
loading
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.
Jagsi, Reshma; Griffith, Kent A; Harris, Eleanor E; Wright, Jean L; Recht, Abram; Taghian, Alphonse G; Lee, Lucille; Moran, Meena S; Small, William; Johnstone, Candice; Rahimi, Asal; Freedman, Gary; Muzaffar, Mahvish; Haffty, Bruce; Horst, Kathleen; Powell, Simon N; Sharp, Jody; Sabel, Michael; Schott, Anne; El-Tamer, Mahmoud.
Afiliação
  • Jagsi R; Emory University, Atlanta, GA.
  • Griffith KA; University of Michigan, Ann Arbor, MI.
  • Harris EE; University of Michigan, Ann Arbor, MI.
  • Wright JL; St Luke's University Health Network, Easton, PA.
  • Recht A; Johns Hopkins University, Baltimore, MD.
  • Taghian AG; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Lee L; Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Moran MS; Northwell, Lake Success, NY.
  • Small W; Yale University, New Haven, CT.
  • Johnstone C; Loyola University Chicago, Maywood, IL.
  • Rahimi A; Medical College of Wisconsin, Milwaukee, WI.
  • Freedman G; University of Texas, Southwestern, Dallas, TX.
  • Muzaffar M; University of Pennsylvania, Philadelphia, PA.
  • Haffty B; East Carolina University, Greenville, NC.
  • Horst K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
  • Powell SN; Stanford University, Stanford, CA.
  • Sharp J; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Sabel M; University of Michigan, Ann Arbor, MI.
  • Schott A; University of Michigan, Ann Arbor, MI.
  • El-Tamer M; University of Michigan, Ann Arbor, MI.
J Clin Oncol ; 42(4): 390-398, 2024 Feb 01.
Article em En | MEDLINE | ID: mdl-38060195
PURPOSE: Multiple studies have shown a low risk of ipsilateral breast events (IBEs) or other recurrences for selected patients age 65-70 years or older with stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (ET) without adjuvant radiotherapy. We sought to evaluate whether younger postmenopausal patients could also be successfully treated without radiation therapy, adding a genomic assay to classic selection factors. METHODS: Postmenopausal patients age 50-69 years with pT1N0 unifocal invasive breast cancer with margins ≥2 mm after BCS whose tumors were estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative with Oncotype DX 21-gene recurrence score ≤18 were prospectively enrolled in a single-arm trial of radiotherapy omission if they consented to take at least 5 years of ET. The primary end point was the rate of locoregional recurrence 5 years after BCS. RESULTS: Between June 2015 and October 2018, 200 eligible patients were enrolled. Among the 186 patients with clinical follow-up of at least 56 months, overall and breast cancer-specific survival rates at 5 years were both 100%. The 5-year freedom from any recurrence was 99% (95% CI, 96 to 100). Crude rates of IBEs for the entire follow-up period for patients age 50-59 years and age 60-69 years were 3.3% (2/60) and 3.6% (5/140), respectively; crude rates of overall recurrence were 5.0% (3/60) and 3.6% (5/140), respectively. CONCLUSION: This trial achieved a very low risk of recurrence using a genomic assay in combination with classic clinical and biologic features for treatment selection, including postmenopausal patients younger than 60 years. Long-term follow-up of this trial and others will help determine whether the option of avoiding initial radiotherapy can be offered to a broader group of women than current guidelines recommend.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article